A Phase 2 interventional study of VVZ-149 Injections and VVZ-149 Injections in Pain, Postoperative / Acute Pain, sponsored by Samsung Medical Center. Completed at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Samsung Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing GlyT2/5HT2A Antagonist VVZ-149 in Pain, Postoperative — none open to participants now, none under way, none of them phase 3. GlyT2/5HT2A Antagonist VVZ-149 · Pain, Postoperative.
Among the 10 studies testing GlyT2/5HT2A Antagonist VVZ-149 in Pain, Postoperative, this one is the 5th largest by enrollment, is the only one that started in 2025, is one of 7 in phase 2, and was the 10th registered.
5,648 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →None of the 10 studies testing GlyT2/5HT2A Antagonist VVZ-149 in Pain, Postoperative is open now. The open studies under Pain, Postoperative, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2025.
This study's enrollment of 66 is below the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 63 across the 10 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 3 most frequent:
Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 6 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing GlyT2/5HT2A Antagonist VVZ-149 in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this phase 2 study is to evaluate the efficacy and safety of PCA regimen of opiranserin (VVZ-149) injections in patients undergoing laparoscopic colectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VVZ-149 Injections
Drug: VVZ-149 Injections · Drug: Fentanyl
VVZ-149 injections mixed with normal saline will be intravenously infused as a 180 mg loading dose over 30 minutes, starting from the initiation of surgical closure. After recovery from anesthesia, VVZ-149 injections will be administered via PCA (VVZ-149 10 mg in 2 mL, 10-min lock-out, basal infusion 6 mL/h)
Also known as: opiranserin Injections
VVZ-149 injections mixed with normal saline will be intravenously infused as a 180 mg loading dose over 30 minutes, starting from the initiation of surgical closure. After recovery from anesthesia, VVZ-149 injections + fentanyl will be administered (VVZ-149 injections 10 mg + fentanyl 4 μg in 2 mL, 10-min lock-out, basal infusion 6 mL/h)
Also known as: opiranserin Injections
VVZ-149 injections mixed with normal saline will be intravenously infused as a 180 mg loading dose over 30 minutes, starting from the initiation of surgical closure. After recovery from anesthesia, VVZ-149 injections + fentanyl will be administered (VVZ-149 injections 10 mg + fentanyl 4 μg in 2 mL, 10-min lock-out, basal infusion 6 mL/h)
Area under the pain intensity-time curve over 8 hours (AUC 8)
Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0 (no pain) to 10 (worst pain imaginable). The area under the curve of the pain intensity over time graph from 0 to 8 hours will be calculated using pain intensity measured at scheduled time points and pre-rescue medication time points, as well as imputed values.
Time frame: 0-8 hours post-emergence
Number of PCA and rescue medication use and requests, and consumption measured at 2 hours for 12 hours post-emergence
The total number of patient-controlled analgesia (PCA) requests and consumption from Time 0 to 12 hours was compared between the two groups.
Time frame: 0-12 hours post-emergence
Number of PCA and rescue medication use and requests, and consumption measured at 6 hours for 24 hours post-emergence
Total amount of PCA and rescue medication consumption from Time 0 to Time 24 hours was compared between the two groups.
Time frame: 0-12 hours post-emergence
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Dec 2025, 4 months.
Of 90 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 4 months is below that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GlyT2/5HT2A Antagonist VVZ-149